// App-Quantinova.ai

2973 : CD269 - A promising target for amanitin based ADCs

Researchers

Presenter

  • Aniko Palfi

Principal Investigators

  • Torsten Hechler

  • Christoph Mueller

  • Andreas Pahl

  • Michael Kulke

Medical Centers

  • Heidelberg Pharma Research GmbH, Ladenburg, Germany

Locations

  • Germany

Companies

  • Heidelberg Pharma Gm

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Apparent diffusion coefficient

Drug/Treatment

  • Adcetris

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved